Anti-NMDA receptor encephalitis pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(6 intermediate revisions by the same user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Anti-NMDA receptor encephalitis}}
{{Anti-NMDA receptor encephalitis}}
{{CMG}} AE{{DMakkar}}
{{CMG}}; AE {{DMakkar}}


==Overview==
==Overview==
Anti-NMDA receptor encephalitis is an autoimmune disorder characterized by autoantibodies targeting GluN1. Tumors, primarily ovarian teratomas in women and testicular teratomas or lung carcinomas in men, are associated. Dysregulation of NMDARs leads to a range of neurological and psychiatric symptoms.


==Pathophysiology==
==Pathophysiology==
Approximately sixty percent of individuals have tumors that contain nerve tissue. Majority of women have ovarian [[teratoma]], while men have tumors like (testicular [[teratoma]] and [[small-cell lung carcinoma)]].


Anti-NMDA receptor encephalitis is predominantly caused by autoantibodies directed against the GluN1 component of the receptor.  
Anti-NMDA receptor encephalitis is predominantly caused by autoantibodies directed against the GluN1 component of the receptor.  
Line 15: Line 17:
*A model for the condition proposes that a decrease in NMDARs in inhibitory GABA neurons and glutamate synapses results in numerous effects, including dysregulation of glutamate release, elevated glutamate levels and excitatory circuits.  
*A model for the condition proposes that a decrease in NMDARs in inhibitory GABA neurons and glutamate synapses results in numerous effects, including dysregulation of glutamate release, elevated glutamate levels and excitatory circuits.  


The clinical syndrome disinhibits the frontostriatal network, resulting in psychotic, catatonic, stiffness, dystonia, and mutistic symptoms. The brainstem central-pattern generator is disinhibited, resulting in complicated movement problems, and the brainstem respiratory network is also disinhibited, leading to respiratory dysfunction.
*The clinical syndrome disinhibits the frontostriatal network, resulting in psychotic, catatonic, stiffness, dystonia, and mutistic symptoms.  
*The brainstem central-pattern generator is disinhibited, resulting in complicated movement problems, and the brainstem respiratory network is also disinhibited, leading to respiratory dysfunction.
NMDAR Dysregulation  Proposed Symptoms
Agonist effect on NMDARs Seizures
Synaptic NMDAR hypofunction Amnesia, psychosis, hypoventilation
Extrasynaptic NMDAR hyperfunction Catatonia, dyskinesias, seizures
Neuronal network imbalance with impaired
intraneuronal activity
 
{| class="wikitable"
 
|+ Synaptic effects and symptoms in anti-NMDARE: a proposed correlation
 
|-
 
! NMDAR Dysregulation
 
! Proposed Symptoms
 
|-
 
| Agonist effect on NMDARs
 
| Seizures
 
|-
 
| Synaptic NMDAR hypofunction
 
| Amnesia, psychosis, hypoventilation
 
|-
 
| Extrasynaptic NMDAR hyperfunction
 
| Catatonia, dyskinesias, seizures
 
|-
 
| Neuronal network imbalance with impaired intraneuronal activity
 
| Seizures
 
|}


==References==
==References==
Line 22: Line 68:
[[Category:Rheumatology]]
[[Category:Rheumatology]]
[[Category:Disease]]
[[Category:Disease]]
 
<ref name="pmid24360484">{{cite journal| author=Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leypoldt F | display-authors=etal| title=Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. | journal=Lancet Neurol | year= 2014 | volume= 13 | issue= 2 | pages= 167-77 | pmid=24360484 | doi=10.1016/S1474-4422(13)70282-5 | pmc=4006368 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24360484  }} </ref>
{{WH}}
{{WH}}
{{WS}}
{{WS}}

Latest revision as of 06:08, 13 May 2023

Anti-NMDA receptor encephalitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Anti-NMDA receptor encephalitis from Other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications, and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Anti-NMDA receptor encephalitis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Anti-NMDA receptor encephalitis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Anti-NMDA receptor encephalitis pathophysiology

CDC on Anti-NMDA receptor encephalitis pathophysiology

Anti-NMDA receptor encephalitis pathophysiology in the news

Blogs on Anti-NMDA receptor encephalitis pathophysiology

Directions to Hospitals Treating Anti-NMDA receptor encephalitis

Risk calculators and risk factors for Anti-NMDA receptor encephalitis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; AE Dheeraj Makkar, M.D.[2]

Overview

Anti-NMDA receptor encephalitis is an autoimmune disorder characterized by autoantibodies targeting GluN1. Tumors, primarily ovarian teratomas in women and testicular teratomas or lung carcinomas in men, are associated. Dysregulation of NMDARs leads to a range of neurological and psychiatric symptoms.

Pathophysiology

Approximately sixty percent of individuals have tumors that contain nerve tissue. Majority of women have ovarian teratoma, while men have tumors like (testicular teratoma and small-cell lung carcinoma).

Anti-NMDA receptor encephalitis is predominantly caused by autoantibodies directed against the GluN1 component of the receptor.

In the acute phase of brain diseases, B cells, plasma cells, CD4 T cells, and, less frequently, CD8 T cells have been detected.

Crossing the blood-brain barrier enables systemically produced antibodies to crosslink NMDA receptors. This leads to their internalization and a severe disruption of synaptic plasticity and NMDA receptor network function.

  • A model for the condition proposes that a decrease in NMDARs in inhibitory GABA neurons and glutamate synapses results in numerous effects, including dysregulation of glutamate release, elevated glutamate levels and excitatory circuits.
  • The clinical syndrome disinhibits the frontostriatal network, resulting in psychotic, catatonic, stiffness, dystonia, and mutistic symptoms.
  • The brainstem central-pattern generator is disinhibited, resulting in complicated movement problems, and the brainstem respiratory network is also disinhibited, leading to respiratory dysfunction.

NMDAR Dysregulation Proposed Symptoms Agonist effect on NMDARs Seizures Synaptic NMDAR hypofunction Amnesia, psychosis, hypoventilation Extrasynaptic NMDAR hyperfunction Catatonia, dyskinesias, seizures Neuronal network imbalance with impaired intraneuronal activity

Synaptic effects and symptoms in anti-NMDARE: a proposed correlation
NMDAR Dysregulation Proposed Symptoms
Agonist effect on NMDARs Seizures
Synaptic NMDAR hypofunction Amnesia, psychosis, hypoventilation
Extrasynaptic NMDAR hyperfunction Catatonia, dyskinesias, seizures
Neuronal network imbalance with impaired intraneuronal activity


Seizures

References

[1] Template:WH Template:WS

  1. Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leypoldt F; et al. (2014). "Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study". Lancet Neurol. 13 (2): 167–77. doi:10.1016/S1474-4422(13)70282-5. PMC 4006368. PMID 24360484.